Crédit Mutuel Equity
VC Fund
Paris, France
Crédit Mutuel Equity is a VC fund in Paris focused on Manufacturing and Health Care. Crédit Mutuel Equity is the Private Equity branch of Crédit Mutuel Alliance Fédérale.
- Total investments:
- 139
- Last investment:
- Lead investor:
- 43%
Last updated:
For AI agents: llms.txt
Industries Crédit Mutuel Equity invests in
Stages Crédit Mutuel Equity invests in
Countries Crédit Mutuel Equity invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 10 contacts → | |||
Round size
- Series A
- $3.5M–$11M
- Private Equity
- $2.6M–$89M
- Venture - Series Unknown
- $5.8M–$46M
Investment Focus
Industry
- Manufacturing 29 (21%)
- Health Care 14 (10%)
- Food and Beverage 11 (8%)
- Medical 8 (6%)
- Construction 8 (6%)
Stage
- Private Equity 76 (55%)
- Venture - Series Unknown 18 (13%)
- Series A 7 (5%)
- Funding Round 7 (5%)
- Seed 6 (4%)
Country
- France 78 (56%)
- Canada 20 (14%)
- Germany 7 (5%)
- United States 4 (3%)
- Switzerland 3 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Jean-Marie Giannettini
Investment Director
|
Investment Director | Total investments: 1 | Find email | |
Antoine ARLET
Directeur de Participations
|
Directeur de Participations | Total investments: 1 | Find email | |
|
Badri Ben Grine
Director
|
Director | Total investments: 1 | Find email | |
Denis Dalmais
Directeur
|
Directeur | Total investments: 1 | Find email | |
| CEO | Total investments: 1 | Find email | ||
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Icentia
|
Icentia provides a range of innovative medical tests for healthcare institutions. They are able to offer valuable solutions for major problems in the field of medical testing. | Venture - Series Unknown / Aug 18, 2026 | |
CELYSTRA Pharma
|
CELYSTRA Pharma is a biopharmaceutical company that identifies and acquires innovative therapies developed internationally and brings them to Canada. The company focuses on making treatments available to patients with rare and specialized diseases who face unmet medical needs. CELYSTRA Pharma licenses and commercializes therapies, working tofacilitate access to medicines that address gaps in current treatment options. It collaborates with international partners to introduce these products into the Canadian healthcare system. The company begins its activities with a Health Canada–approved treatment for familial chylomicronemia syndrome, a rare genetic disorder. CELYSTRA Pharma concentrates on underserved patient populations and structured market access for novel therapies. | $14.7M / Seed / May 05, 2026 | |
Arbutus Medical
|
Every hospital in the world is faced with a major challenge - the rising cost of heathcare - we want to do something about it. Arbutus Medical’s purpose is to develop a portfolio of “frugal innovation” devices that save costs for hospitals and improve access to orthopedic surgery for 5 million patients by 2030. Arbutus Medical's flagshipproduct is a radically affordable orthopaedic power tool system that is used in North American Trauma Centers, veterinary hospitals, military deployments, NGO missions, and hospitals in over 30 low- and middle-income countries worldwide. | $6.8M / Feb 17, 2026 | |
Blue Charm Adherence
|
Blue Charm Adherence is a healthcare company providing interactive patient platforms and behavioural modification tools which improve health literacy and access to specialty medications. The Blue Charm mobile application offers a multi-tiered solution to medication non-adherence. | $4M / Seed / Sep 09, 2025 | |
Socomore
|
Socomore has been creating, manufacturing and commercialising expert solutions for preparation, protection, treatment or control of metallic or composite materials. Our 4 activities are : › Critical surface treatment and preparation through the Socomore, Magchem and Dysol product ranges, the majority of which are approved by the main aerospacemanufacturers (OEMs). › Non-destructive testing through BabbCo’s range of consumable products, equipment, and Mag Rubber replication material. › Structural adhesives and moldable shims through the Dynamold product range. › Coatings for erosion and lightning strike protection, as a result of our recent agreement with LORD Corporation. This innovative range of functionalized coating solutions includes conductive coatings, mid coats, primers, top coats and wash primers. | Jun 20, 2025 | |
|
Socomore
|
Socomore has been creating, manufacturing and commercialising expert solutions for preparation, protection, treatment or control of metallic or composite materials. Our 4 activities are : › Critical surface treatment and preparation through the Socomore, Magchem and Dysol product ranges, the majority of which are approved by the main aerospacemanufacturers (OEMs). › Non-destructive testing through BabbCo’s range of consumable products, equipment, and Mag Rubber replication material. › Structural adhesives and moldable shims through the Dynamold product range. › Coatings for erosion and lightning strike protection, as a result of our recent agreement with LORD Corporation. This innovative range of functionalized coating solutions includes conductive coatings, mid coats, primers, top coats and wash primers. | Jun 20, 2025 | |
Spare-it
|
Spare-it offers a solution to track office waste streams in real-time. | $4.2M / Seed / Apr 15, 2025 | |
HiringBranch
|
HiringBranch is an AI-powered soft skills and language assessment hiring solution that specializes in human resources. | $3.5M / Series A / Dec 10, 2024 | |
Zaddons
|
ZADDONS and its product extensions were born from HRIS platform efficiency and productivity gaps identified by users. Deep within our DNA resides a desire to develop and deliver the most advanced, user-friendly scheduling solutions that enable workforce efficiency without distraction. | $3.5M / Venture - Series Unknown / Jun 13, 2024 | |
Netskrt
|
Netskrt revolutionizes the Internet experience by extending the reach of internet video to the outskirts of the network. Traditionally, rail and air passengers have limited access to the internet content they want to watch. With the Netskrt mCDN, they can use their existing internet video subscriptions just like they do at home. | $7.3M / Series A / May 01, 2024 | |
| See all 139 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Crédit Mutuel Equity invest in?
Crédit Mutuel Equity invests primarily in Manufacturing, Health Care and Food and Beverage startups, most often at Private Equity and Venture - Series Unknown stage. Most of the 139 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Crédit Mutuel Equity's check size?
Crédit Mutuel Equity typically joins rounds of $3.5M–$11M at Series A, $2.6M–$89M at Private Equity and $5.8M–$46M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Crédit Mutuel Equity participates in.
How do I contact Crédit Mutuel Equity?
Public channels for Crédit Mutuel Equity include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Crédit Mutuel Equity?
The team at Crédit Mutuel Equity includes Jean-Marie Giannettini (Investment Director), Antoine ARLET (Directeur de Participations) and Badri Ben Grine (Director), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
